Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Denali Therapeutics Trading Up 0.3 %

Denali Therapeutics stock opened at $21.25 on Thursday. The stock has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. The company has a 50-day moving average price of $24.34 and a 200 day moving average price of $24.88. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm earned ($0.72) EPS. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

DNLI has been the subject of a number of analyst reports. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $31.00 target price for the company. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. William Blair started coverage on shares of Denali Therapeutics in a research report on Friday, January 3rd. They set an “outperform” rating for the company. Finally, HC Wainwright dropped their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.91.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in shares of Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock worth $4,525,000 after acquiring an additional 22,900 shares during the last quarter. TD Asset Management Inc raised its holdings in shares of Denali Therapeutics by 4.5% in the 2nd quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock valued at $4,160,000 after buying an additional 7,766 shares during the period. Arizona State Retirement System lifted its stake in Denali Therapeutics by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after acquiring an additional 2,730 shares in the last quarter. American Century Companies Inc. boosted its holdings in Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after acquiring an additional 63,058 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Denali Therapeutics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock worth $32,913,000 after purchasing an additional 84,522 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.